Background. Central nervous system (CNS) involvement with Blastomyces dermatitidis is an uncommon and potentially fatal complication of blastomycosis.
nary, extrapulmonary, or both. Single organ involvement with B. dermatitidis has been diagnosed in 69%-80% of cases, with the most common single organ involved being the lungs [5] [6] [7] [8] . The most common sites of extrapulmonary infection with or without coexisting pulmonary infection are, in decreasing frequency, the skin, bony structures, and genitourinary system [1] .
Clinical involvement of the central nervous system (CNS) accounts for 5%-10% of extrapulmonary blastomycosis in clinical reviews [1, 2, 9] but has been observed in up to 33% of patients in autopsy series [10] . The last major review of CNS blastomycosis was published 30 years ago [9] . Most subsequent reports of CNS blastomycosis have been limited to single case reports or small series that were reported prior to the widespread use of modern imaging modalities and expanded-spectrum azole therapy. We undertook this multicenter review of CNS blastomycosis at our institutions with a focus on clinical presentation, methods of diagnosis, recent trends in antifungal therapy, and outcomes. 
PATIENTS AND METHODS
Patients admitted to our institutions and diagnosed with blastomycosis from 1990 through June 2008 were identified by investigators at their respective institutions. The medical records of these patients were reviewed, and those patients with clinical or microbiological evidence of CNS involvement with B. dermatitidis were included in this study. Institutional Review Board approval was obtained. Data collected from the patients' medical records included demographic information, past medical history, presenting signs and symptoms, laboratory and imaging results, antifungal agents used, any invasive neurological procedures performed, clinical outcomes and duration of follow-up, and available follow-up laboratory or imaging results obtained. The data were collected by an investigator at each institution with use of the same data collection form and were then compiled by the lead investigator.
A case of blastomycosis was defined as a positive culture for B. dermatitidis from any source or histopathological evidence of B. dermatitidis from any tissue. In addition, cases were included if B. dermatitidis antibodies or antigen were detected in a patient with a clinical illness compatible with blastomycosis. We defined CNS blastomycosis as disease involving the brain or spinal cord and surrounding membranes and fluid. Proven CNS blastomycosis was defined as a positive CNS culture for B. dermatitidis or histopathological evidence of B. dermatitidis from cerebrospinal fluid (CSF), brain parenchyma, or surrounding tissues. Probable CNS blastomycosis was defined as microbiological or histopathological evidence of B. dermatitidis in a non-CNS site along with abnormal CNS imaging or abnormal CSF findings that improved after treatment that would be considered appropriate for CNS blastomycosis. Possible CNS blastomycosis was defined as microbiological or histopathological evidence of B. dermatitidis in a non-CNS site along with concurrent abnormal CNS imaging or abnormal CSF findings but without follow-up CNS studies. Patients whose only evidence of B. dermatitidis was an indirect marker for the presence of B. dermatitidis (antibodies or antigen) from a CNS site along with other clinical findings compatible with blastomycosis were considered to have possible CNS blastomycosis.
Patients were classified as immunosuppressed if they fulfilled at least 1 of the following criteria: human immunodeficiency virus seropositive with a CD4 lymphocyte count of !200 cells/ mL, daily use of 110 mg of prednisone or its equivalent for at least 4 weeks, anti-tumor necrosis factor therapy within the past 6 months, solid organ or hematopoetic stem cell transplant receiving chronic immunosuppressive therapy, malignancy requiring cytotoxic chemotherapy, the receipt of systemic immunomodulators for other medical conditions, or diabetes mellitus. For purposes of this review, the presence of diabetes mellitus was included in the criteria for immunosuppression because blastomycosis has been associated with diabetes mellitus [11] .
RESULTS
We identified 22 patients with a diagnosis of CNS blastomycosis for possible enrollment. Thirteen of these 22 patients were classified as having proven cases of CNS blastomycosis. Five were classified as having probable cases, and 4 had possible cases. Demographic information about the patients is presented in Table 1 . Seventeen patients (77.2%) were male. Twelve patients (54.5%) were classified as immunocompromised, of whom 7 had diabetes mellitus as the sole criteria for immunosuppression. Details regarding their clinical presentations and findings are presented in Table 2 .
All patients had neurological complaints or clinical evidence of neurological dysfunction at the time of presentation. The most common neurological complaint or finding was headache, seen in 19 patients (86.3%), followed by focal neurological deficit, altered mental status, vision changes, and seizures. Seventeen (77.2%) had evidence of involvement of other organ systems in addition to the CNS. Of these 17 patients, 6 had pulmonary infections, 3 had cutaneous infections, 1 had bone infection, and 7 had evidence of multiple non-CNS organ involvement. Of the 5 patients with evidence of neurological involvement only, 3 were immunocompetent and 2 had diabetes mellitus.
All patients had abnormal radiographic imaging findings of the CNS (Table 2) . Four patients had computed tomography (CT) imaging only, 5 had magnetic resonance imaging (MRI) only, and 13 had both. Twelve of these 13 had abnormalities in both CT and MRI findings. One patient had normal CT findings, whereas MRI demonstrated diffuse meningeal enhancement and a basal ganglia lesion. MRI often provided more details than CT, especially in regards to the posterior fossa regions. In those patients with brain masses, the majority had a single lesion on CNS imaging. Three patients had multiple brain masses observed on either CT or MRI.
Of 11 patients in whom a CSF specimen was obtained via lumbar puncture for analysis, 10 had evidence of pleocytosis ( Table 2 ). The pleocytosis was lymphocyte predominant in 5 patients, neutrophil predominant in 4, and unavailable in 1 patient. CSF protein levels were abnormal in 10 of 11 patients in whom it was measured; 9 had elevated levels of CSF protein, and 1 patient had a low CSF protein level. Of the 11 patients in whom CSF was obtained, only 1 had yeast forms consistent with B. dermatitidis seen on initial examination of CSF. Five of these 11 had positive CSF cultures for B. dermatitidis. All 5 patients with positive CSF cultures had evidence of CSF pleocytosis, and 3 of these 5 also had evidence of leptomeningeal enhancement on imaging studies.
Three patients had CSF samples analyzed for the presence of B. dermatitidis antigen (Mira Vista Diagnostics), and all 3 yielded positive results. These 3 patients had CSF pleocytosis, and 2 of these 3 had evidence of meningeal enhancement on brain imaging. Two of these 3 had positive CSF cultures for B. dermatitidis. The other patient had a clinical course compatible with disseminated blastomycosis, including pulmonary infiltrates, but B. dermatitidis was never successfully isolated from this patient. Antibodies to B. dermatitidis were detectable in the CSF of 2 patients with proven CNS blastomycosis; 1 via complement fixation and 1 via immunodiffusion. Urinary Histoplasma capsulatum antigen test results were positive in 4 patients-2 with proven, 1 with probable, and 1 with possible CNS blastomycosis. One of these 4 had no evidence of non-CNS blastomycosis. Another patient with proven CNS blastomycosis and a positive CSF B. dermatitidis antigen result also had a positive CSF H. capsulatum antigen result.
Details regarding treatment and outcomes are provided in Tables 2 and 3 . All patients received antifungal therapy with a formulation of amphotericin B (AmB): 11 received AmB-deoxycholate, 9 received a lipid formulation of AmB, and 2 received both formulations sequentially. Two patients received only AmB during their treatment courses, and 3 received AmB and azole therapy simultaneously. The remaining 17 patients received an initial course of AmB followed by oral azole therapy. The median time of initial AmB therapy was 25.5 days (range, 6-63 days). Following an initial course of AmB, 7 received fluconazole, 7 received voriconazole, and 1 received itraconazole. Two additional patients who received fluconazole were changed to itraconazole and voriconazole, respectively.
Four patients died of complications related to CNS blastomycosis; 2 of these 4 were immunocompromised. One patient (Patient 20) was treated initially with AmB-deoxycholate for a cerebral mass but was noncompliant with therapy. This patient had evidence of new brain masses ∼4 months later and died during subsequent therapy with AmB-deoxycholate followed by fluconazole. The presumptive cause of death was cerebral edema with herniation. The other 3 patients (Patients 4, 6, and 19) had altered mental status at the time of presentation. Two of these 3 had evidence of cerebellar herniation on initial CNS imaging, and 1 had evidence of ventricular dilation. All 3 received AmB-containing regimens. These patients died 9, 48, and 46 days following initiation of antifungal therapy. Fourteen patients (63.6%) had follow-up CNS imaging performed after antifungal therapy was initiated. Nine (64.2%) of these 14 patients had improvement or resolution of their initial findings on CNS imaging. Three demonstrated stable radiologic findings at 1 week to 2 months after initiation of therapy, and 2 had worsening of their findings. Both of these 2 with worsening CNS imaging findings had been noncompliant with therapy.
DISCUSSION
CNS involvement remains a serious but uncommon manifestation of blastomycosis. Four (18.1%) of the 22 patients in this review died as a direct result of this infection. Delay in presentation and/or diagnosis has been reported to play a significant role in the high mortality rate [12, 13] . CNS involvement with B. dermatitidis may present as meningitis, intracranial mass lesions, or abscesses of the spinal cord or epidural space. [9, [14] [15] [16] [17] . Most cases of CNS blastomycosis have been associated with concomitant infection at non-CNS sites. There are few reports of isolated CNS blastomycosis [14, 15] .
B. dermatitidis meningitis is associated with a CSF pleocytosis, which may demonstrate a lymphocytic or neutrophilic predominance. The CSF protein level is usually elevated, and CSF glucose level is typically normal or decreased. Isolation of B dermatitidis from culture of CSF obtained via lumbar puncture is uncommon based on prior reports; however, culture of ventricular fluid may be associated with greater sensitivity [2] . One study involving CNS blastomycosis found that CSF culture was positive in only 2 of 22 patients [15] . Eleven of our patients had CSF fungal cultures obtained, and 5 (45.4%) of these 11 were positive for B. dermatitidis. All had evidence of CSF pleocytosis, and 3 of these 5 patients had evidence of leptomeningeal enhancement on CNS imaging. CSF culture was negative among patients with mass lesions only.
Previous reports have suggested that CNS blastomycosis without evidence of infection at other sites is rare [9, 14] . In this report, 5 patients (22.7%) had only CNS involvement on the basis of clinical and radiographic assessment. In this ret- Fluconazole, then itraconazole 1 2 months, then 10 months 0 AmB repeated 3ϫ, followed by fluconazole 1 3 months, 4 months, 2 months, followed by 12 months 0
AmB plus fluconazole 1 1.5 months 1 AmB plus flucytosine, followed by AmB plus voriconazole 1 1 week, followed by 2.5 months 1 AmB plus voriconazole, followed by voriconazole 1 1 month, followed by 12 months planned 0
rospective review, it is possible that concomitant infection at other sites was overlooked.
In patients with intracranial mass lesions, both single and multiple lesions were seen, and the cerebellum was frequently involved. This finding has been previously reported in association with B. dermatitidis [18] [19] [20] . A review of CNS blastomycosis by Gonyea [9] in 1979 suggested that the coexistence of blastomycotic meningitis and cerebral brain masses was rare. In our patients, 4 had brain masses together with radiological evidence of leptomeningeal enhancement and/or CSF findings indicating meningitis. This may reflect the broader use of MRI as a diagnostic tool in patients with proven or suspected CNS infections. Only 1 patient had normal CT findings with subsequent abnormal MRI findings. Given that treatment for CNS blastomycosis differs from treatment for other forms of blastomycosis, it is reasonable to consider MRI as the imaging study of choice when evaluating for CNS blastomycosis.
A neurosurgical procedure, excluding lumbar puncture, was used in 8 patients and was often helpful in leading to a diagnosis. Pathologists familiar with the characteristic forms of B. dermatitidis are required to make a reliable diagnosis via histopathological examination. Surgery has been recommended in the diagnosis of CNS blastomycosis as well as for management of osteomyelitis and for mass lesions [18] . In our patients, neurosurgery was used mostly as an aid to diagnosis. On the basis of our findings, if blastomycosis is diagnosed at a non-CNS site, it is reasonable to treat empirically for CNS blastomycosis in patients with abnormal CNS imaging or CSF results. Under any circumstances, close follow-up should be maintained, including repeated CNS imaging or repeated lumbar punctures to document improvement in findings. In our patients with follow-up imaging, most experienced improvement by 2 months of therapy.
Recognizing that CSF culture is insensitive for the specific diagnosis of CNS blastomycosis, detection of B. dermatitidis antigen in the CSF may be useful. Clinicians should be aware of the assay's limitations, including crossreactions with other fungal infections, particularly H. capsulatum. Three of our patients had detection of B. dermatitidis antigen in their CSF; all 3 had CSF pleocytosis, and 2 had evidence of leptomeningeal enhancement on MRI as part of their imaging findings. In 1 of these patients (Patient 21), CSF antigen detection was the only proof of blastomycosis. This patient also had pulmonary findings suggestive of blastomycosis.
Recommended treatment for CNS blastomycosis is a lipid formulation of AmB for 4-6 weeks, followed by an oral azole for at least 1 year [21, 22] . In animal models, liposomal amphotericin B is associated with higher CNS drug levels than AmB-deoxycholate [23] . Observations from this retrospective study support a recommendation of a lipid formulation of AmB over AmB-deoxycholate for CNS blastomycosis. More recently, patients with CNS blastomycosis have been treated with shorter courses of AmB, followed by a prolonged course of azole therapy [24] [25] [26] [27] . No prospective clinical trials have been performed to evaluate the ideal length of initial therapy with AmB. Several of our patients had successful outcomes with shorter initial courses of AmB than are currently recommended by the latest guidelines, followed by oral azole therapy.
In our patients, fluconazole and voriconazole were used much more frequently than itraconazole, although all 3 azoles are currently recommended. Fluconazole, however, has previously been associated with higher rates of treatment failure in pulmonary and extrapulmonary blastomycosis unless higher doses are used [28] . Itraconazole, the drug of choice for nonlife-threatening, non-CNS blastomycosis, was not used much in the treatment of CNS blastomycosis, possibly because of concerns regarding the relatively poor concentrations achieved in the CNS [29, 30] . However, there are case reports using itraconazole in the treatment of CNS blastomycosis [31] . In addition, the Infectious Diseases Society of America clinical practice guidelines for histoplasmosis list itraconazole as the recommended azole for CNS histoplasmosis following initial therapy with AmB [32] .
Voriconazole is known to have good CNS penetration and is the recommended primary treatment for CNS aspergillosis [33] . It has also been used successfully in the treatment of CNS histoplasmosis [34] . The utility of voriconazole for the treatment of CNS blastomycosis has been limited to case reports, but these observations have been encouraging. On the basis of these anecdotes and our observations, we favor the use of voriconazole as the azole of choice for treatment of CNS blastomycosis after initial therapy with AmB. In this study, all but 1 patient treated with a voriconazole-containing regimen had a favorable outcome. One patient treated with a voriconazolecontaining regimen died, but this patient had evidence of advanced neurological disease at the time of presentation and died despite a prolonged course of both a lipid formulation of AmB and voriconazole. Fluconazole administered at higher doses is also an effective alternative for CNS blastomycosis if voriconazole is unavailable, contraindicated, or poorly tolerated. Itraconazole is suggested as an option for the treatment of CNS blastomycosis in recently published Infectious Diseases Society of America treatment guidelines for CNS blastomycosis, although few of our patients were treated with itraconazole once CNS involvement was suspected. Three patients were treated with combination antifungal therapy (amphotericin B plus azole therapy). Two of these 3 patients died, and the severity of their illness at the time of presentation may have influenced clinical decisions regarding the use of combination antifungal therapy. Overall, 4 patients died as a result of CNS blastomycosis. Death was usually a result of complications related to increased intracranial pressure and cerebral herniation. In patients with evidence of increased intracranial pressure, aggressive interventions at controlling the pressure, in addition to antifungal therapy, may be warranted.
Serum azole levels were not recorded in our patients. More recently, therapeutic drug monitoring for azoles has become common and is now recommended [22] . Given the severity of CNS blastomycosis, we would agree with the recommendations for therapeutic drug monitoring.
CNS involvement with blastomycosis remains a serious but uncommon complication of this systemic infection. A high clinical index of suspicion remains essential in arriving at a timely diagnosis of CNS blastomycosis. Diagnostic tools to aid good clinical acumen remain limited for blastomycosis. Serologic markers of blastomycosis are available but have poor specificity and unknown sensitivity in this setting. When CNS involvement with B. dermatitidis is suspected, treatment should involve lipid formulation of AmB followed by oral azole therapy, preferably voriconazole. Current guidelines recommend 4-6 weeks of lipid formulation of AmB before stepping down to oral azole therapy. It is common practice to transition from lipid formulation of AmB to an oral azole after 2 weeks of therapy, provided there has been a good clinical response and careful follow-up can be maintained. However, there is much variability in response to therapy among individual patients, and thus, treatment decisions must be addressed on a case-bycase basis. Prompt recognition of this complication of blastomycosis and early institution of therapy remain critical in the successful management of this infection.
